Combination vaccines: Synergistic simultaneous induction of antibody and T-cell immunity

Expert Review of Vaccines

Volumn 6, Issue 1, 2007, Pages 111-121

  Moore, Anne C ^a,b   Hutchings, Claire L ^b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Antibodies; Malaria; Recombinant; Subunit; T cell; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; ALUMINUM POTASSIUM SULFATE; ALUMINUM SALT; ANTIGEN; AS 02A; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DNA VACCINE; HEPATITIS B SURFACE ANTIGEN; IMMUNOLOGICAL ADJUVANT; LIPOSOME; MALARIA POXVIRUS PLUS PROTEIN SUBUNIT VACCINE; MALARIA VACCINE; MONTANIDE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NAKED DNA; POLYGLACTIN; PROTOZOAL VACCINE; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG; VACCINIA VACCINE; VIROSOME; VIRUS VACCINE; VIRUS VECTOR;

ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIGEN PRESENTATION; B LYMPHOCYTE ACTIVATION; CD8+ T LYMPHOCYTE; CELL KILLING; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DNA IMMUNIZATION; HEPATITIS B; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; LIFE CYCLE; MAJOR HISTOCOMPATIBILITY COMPLEX; MALARIA CONTROL; MALARIA FALCIPARUM; MEROZOITE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PLASMODIUM MALARIAE; PRIORITY JOURNAL; REVIEW; SPOROZOITE; T LYMPHOCYTE ACTIVATION; TH1 CELL;

ANIMALS; COMMUNICABLE DISEASES; HUMANS; IMMUNITY, CELLULAR; MALARIA; POXVIRIDAE; T-LYMPHOCYTES; VACCINES, COMBINED; VACCINES, SUBUNIT; VIRAL VACCINES;

EID: 33846930662     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.6.1.111     Document Type: Review

References (94)

1. Nossal GJ. The Global Alliance for Vaccines and Immunization - a millennial challenge. Nat. Immunol. 1(1), 5-8 (2000).
2. Nossal GJ. A healthier climate for the funding of vaccine research. Nat. Immunol. 5(5), 457-459 (2004).
3. Hanke T, McMichael AJ, Mwau M et al. Development of a DNA-MVA/HIVA vaccine for Kenya. Vaccine 20(15), 1995-1998 (2002).
4. Moore AC, Hill AV. Progress in DNA-based heterologous prime-boost immunization strategies for malaria. Immunol. Rev. 199, 126-143 (2004).
5. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4(4), 397-402 (1998).
6. Good MF, Doolan DL. Immune effector mechanisms in malaria. Curr. Opin. Immunol. 11(4), 412-419 (1999).
7. Letvin NL, Barouch DH, Montefiori DC. Prospects for vaccine protection against HIV-1 infection and AIDS. Ann. Rev. Immunol. 20, 73-99 (2002).
8. Igietseme JU, Eko FO, He H, Black CM. Antibody regulation of T-cell immunity: implications for vaccine strategies against intracellular pathogens. Expert Rev. Vaccines 3(1), 23-34 (2003). • Outlines the essential role of antibodies in complementing the T-cell response to intracellular pathogens.
9. Houghton AN, Gold JS, Blachere NE. Immunity against cancer: lessons learned from melanoma. Curr. Opin. Immunol. 13(2), 134-140 (2001).
10. Sedegah M, Weiss W, Sacci JB Jr et al. Improving protective immunity induced by DNA-based immunization: priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus. J. Immunol. 164(11), 5905-5912 (2000).
11. Srivastava IK, Liu MA. Gene vaccines. Ann. Intern. Med. 138(7), 550-559 (2003).
12. Hutchings CL, Gilbert SC, Hill AV, Moore AC. Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity. J. Immunol. 175(1), 599-606 (2005). •• The first study to demonstrate the enhanced T-cell and antibody responses induced by combining and concurrently immunizing with a poxvirus-based and subunit protein vaccine.
13. Gallup JL, Sachs JD. The economic burden of malaria. Am. J. Trop. Med. Hyg. 64(Suppl. 1-2), 85-96 (2001).
14. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434(7030), 214-217 (2005).
15. Marshall E. Malaria. A renewed assault on an old and deadly foe. Science 290(5491), 428-430 (2000).
16. Plebanski M, Hill AV. The immunology of malaria infection. Curr. Opin. Immunol. 12(4), 437-441 (2000).
17. Bull PC, Lowe BS, Kortok M et al. Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria. Nat. Med. 4(3), 358-360 (1998).
18. Dodoo D, Staalsoe T, Giha H et al. Antibodies to variant antigens on the surfaces of infected erythrocytes are associated with protection from malaria in Ghanaian children. Infect. Immun. 69(6), 3713-3718 (2001).
19. Clyde DF, Most H, McCarthy VC, Vanderberg JP. Immunization of man against sporozite-induced Falciparum malaria. Am. J. Med. Sci. 266(3), 169-177 (1973).
20. Nussenzweig RS, Vanderberg J, Most H, Orton C. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature 216(5111), 160-162 (1967).
21. Webster DP, Dunachie S, Vuola JM et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc. Natl Acad. Sci. USA 102(13), 4836-4841 (2005). • The first report of sterile protection against malaria with vectored vaccines in a sporozoite challenge study. One volunteer showed sterile protection that was maintained at 20 months after vaccination and was associated with circulating central memory T cells.
22. Trombetta ES, Mellman I. Cell biology of antigen processing in vitro and in vivo. Ann. Rev. Immunol. 23, 975-1028 (2005).
23. Kutubuddin M, Simons J, Chow M. Poliovirus-specific major histocompatibility complex class I-restricted cytolytic T-cell epitopes in mice localize to neutralizing antigenic regions. J. Virol. 66(10), 5967-5974 (1992).
24. Schirmbeck R, Melber K, Mertens T, Reimann J. Antibody and cytotoxic T-cell responses to soluble hepatitis B virus (HBV) S antigen in mice: implication for the pathogenesis of HBV-induced hepatitis. J. Virol. 68(3), 1418-1425 (1994).
25. Wraith DC, Vessey AE, Askonas BA. Purified influenza virus nucleoprotein protects mice from lethal infection. J. Gen. Virol. 68(Pt 2), 433-440 (1987).
26. Yamada A, Ziese MR, Young JF, Yamada YK, Ennis FA. Influenza virus hemagglutinin-specific cytotoxic T cell response induced by polypeptide produced in Escherichia coli. J. Exp. Med. 162(2), 663-674 (1985).
27. Moore A, McCarthy L, Mills KH. The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1. Vaccine 17(20-21), 2517-2527 (1999).
28. Nair S, Zhou X, Huang L, Rouse BT. Class I restricted CTL recognition of a soluble protein delivered by liposomes containing lipophilic polylysines. J. Immunol. Methods 152(2), 237-243 (1992).
29. Mowat AM, Donachie AM, Reid G, Jarrett O. Immune-stimulating complexes containing Quil A and protein antigen prime class I MHC-restricted T lymphocytes in vivo and are immunogenic by the oral route. Immunology 72(3), 317-322 (1991).
30. + cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature 344(6269), 873-875 (1990).
31. van Binnendijk RS, van Baalen CA, Poelen MC et al. Measles virus transmembrane fusion protein synthesized de novo or presented in immunostimulating complexes is endogenously processed for HLA class I- and class II-restricted cytotoxic T cell recognition. J. Exp. Med. 176(1), 119-128 (1992).
32. Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat. Med. 11(Suppl. 4), S63-S68 (2005).
33. Alonso PL, Sacarlal J, Aponte JJ et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 366(9502), 2012-2018 (2005). • Demonstrates that a subunit malaria vaccine can induce some level of durable protection in a target population.
34. Alonso PL, Sacarlal J, Aponte JJ et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364(9443), 1411-1420 (2004). • The first report of clear and significant protection against clinical malaria in African children using the RTS,S/AS02A vaccine. Protection against both clinical disease and parasitaemia was observed that lasted several months.
35. Garcon N, Heppner DG, Cohen J. Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant. Expert Rev. Vaccines 2(2), 231-238 (2003).
36. Heppner DG Jr, Kester KE, Ockenhouse CF et al. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine 23(17-18), 2243-2250 (2005).
37. Lalvani A, Moris P, Voss G et al. Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine. J. Infect. Dis. 180(5), 1656-1664 (1999).
38. Reece WH, Pinder M, Gothard PK et al. A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat. Med. 10(4), 406-410 (2004).
39. Hill AV. Pre-erythrocytic malaria vaccines: towards greater efficacy. Nat. Rev. Immunol. 6(1), 21-32 (2006).
40. Birkett A, Lyons K, Schmidt A et al. A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts. Infect. Immun. 70(12), 6860-6870 (2002).
41. Nardin EH, Oliveira GA, Calvo-Calle JM et al. Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes. Infect. Immun. 72(11), 6519-6527 (2004).
42. Oliveira GA, Wetzel K, Calvo-Calle JM et al. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a Phase I trial. Infect. Immun. 73(6), 3587-3597 (2005).
43. Walther M, Dunachie S, Keating S et al. Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. Vaccine 23(7), 857-864 (2005).
44. Lopez JA, Weilenman C, Audran R et al. A synthetic malaria vaccine elicits a potent CD8(+) and CD4(+) T lymphocyte immune response in humans. Implications for vaccination strategies. Eur. J. Immunol. 31(7), 1989-1998 (2001).
45. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Ann. Rev. Immunol. 15, 617-648 (1997).
46. Donnelly JJ, Wahren B, Liu MA. DNA vaccines: progress and challenges. J. Immunol. 175(2), 633-639 (2005).
47. Ulmer JB, Deck RR, DeWitt CM et al. Protective immunity by intramuscular injection of low doses of influenza virus DNA vaccines. Vaccine 12(16), 1541-1544 (1994).
48. Ulmer JB, Donnelly JJ, Parker SE et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259(5102), 1745-1749 (1993).
49. Wolff JA, Malone RW, Williams P et al. Direct gene transfer into mouse muscle in vivo. Science 247(4949 Pt 1), 1465-1468 (1990).
50. Moore AC, Kong WP, Chakrabarti BK, Nabel GJ. Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice. J. Virol. 76(1), 243-250 (2002).
51. Sedegah M, Hedstrom R, Hobart P, Hoffman SL. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc. Natl Acad. Sci. USA 91(21), 9866-9870 (1994).
52. Degano P, Schneider J, Hannan CM, Gilbert SC, Hill AV. Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models. Vaccine 18(7-8), 623-632 (1999).
53. Leitner WW, Seguin MC, Ballou WR et al. Immune responses induced by intramuscular or gene gun injection of protective deoxyribonucleic acid vaccines that express the circumsporozoite protein from Plasmodium berghei malaria parasites. J. Immunol. 159(12), 6112-6119 (1997).
54. Calarota S, Bratt G, Nordlund S et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 351(9112), 1320-1325 (1998).
55. MacGregor RR, Boyer JD, Ugen KE et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J. Infect. Dis. 178(1), 92-100 (1998).
56. Wang R, Doolan DL, Le TP et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282(5388), 476-480 (1998).
57. McConkey SJ, Reece WH, Moorthy VS et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. 9(6), 729-735 (2003).
58. + T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus. J. Immunol. 172(5), 3094-3100 (2004).
59. Ockenhouse CF, Sun PF, Lanar DE et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a poxvectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J. Infect. Dis. 177(6), 1664-1673 (1998).
60. Amara RR, Villinger F, Staprans SI et al. Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines. J. Virol. 76(15), 7625-7631 (2002).
61. Keating SM, Bejon P, Berthoud T et al. Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J. Immunol. 175(9), 5675-5680 (2005).
62. Letvin NL, Huang Y, Chakrabarti BK et al. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. J. Virol. 78(14), 7490-7497 (2004).
63. McShane H, Behboudi S, Goonetilleke N, Brookes R, Hill AV. Protective immunity against Mycobacterium tuberculosis induced by dendritic cells pulsed with both CD8(+)- and CD4(+)-T-cell epitopes from antigen 85A. Infect. Immun. 70(3), 1623-1626 (2002).
64. Moorthy VS, Imoukhuede EB, Keating S et al. Phase I evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men. J. Infect. Dis. 189(12), 2213-2219 (2004).
65. Moorthy VS, Pinder M, Reece WH et al. Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults. J. Infect. Dis. 188(8), 1239-1244 (2003).
66. Vuola JM, Keating S, Webster DP et al. Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J. Immunol. 174(1), 449-455 (2005).
67. Sullivan NJ, Geisbert TW, Geisbert JB et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424(6949), 681-684 (2003).
68. Dunachie SJ, Walther M, Vuola JM et al. A clinical trial of immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. Vaccine 24(15), 2850-2859 (2006).
69. Boudet F, Chevalier M, Jourdier TM, Tartaglia J, Moste C. Modulation of the antibody response to the HIV envelope subunit by co-administration of infectious or heat-inactivated canarypoxvirus (ALVAC) preparations. Vaccine 19(30), 4267-4275 (2001).
70. Phumiamorn S, Sato H, Kamiyama T, Kurokawa M, Shiraki K. Induction of humoral and cell-mediated immunity to hepatitis B surface antigen by a novel adjuvant activity of Oka varicella vaccine. J. Gen. Virol. 84(Pt 2), 287-291 (2003).
71. Ramirez JC, Gherardi MM, Esteban M. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J. Virol. 74(2), 923-933 (2000).
72. Cassese G, Arce S, Hauser AE et al. Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. J. Immunol. 171(4), 1684-1690 (2003).
73. Guyre PM, Graziano RF, Goldstein J et al. Increased potency of Fc-receptor-targeted antigens. Cancer Immunol. Immunother. 45(3-4), 146-148 (1997).
74. Moore T, Ekworomadu CO, Eko FO et al. Fc receptor-mediated antibody regulation of T cell immunity against intracellular pathogens. J. Infect. Dis. 188(4), 617-624 (2003).
75. Fanger NA, Voigtlaender D, Liu C et al. Characterization of expression, cytokine regulation, and effector function of the high affinity IgG receptor Fc γ RI (CD64) expressed on human blood dendritic cells. J. Immunol. 158(7), 3090-3098 (1997).
76. Geissmann F, Launay P, Pasquier B et al. A subset of human dendritic cells expresses IgA Fc receptor (CD89), which mediates internalization and activation upon cross-linking by IgA complexes. J. Immunol. 166(1), 346-352 (2001).
77. Gosselin EJ, Wardwell K, Gosselin DR et al. Enhanced antigen presentation using human Fc γ receptor (monocyte/macrophage)-specific immunogens. J. Immunol. 149(11), 3477-3481 (1992).
78. Regnault A, Lankar D, Lacabanne V et al. Fcγ receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J. Exp. Med. 189(2), 371-380 (1999).
79. Mills KH. Immunity to Bordetella pertussis. Microbes Infect. 3(8), 655-677 (2001).
80. + Th1 cells. Vaccine 13(18), 1741-1749 (1995).
81. Singh M, Kazzaz J, Ugozzoli M et al. Polylactide-co-glycolide microparticles with surface adsorbed antigens as vaccine delivery systems. Curr. Drug Deliv. 3(1), 115-120 (2006).
82. Westerfeld N, Zurbriggen R. Peptides delivered by immunostimulating reconstituted influenza virosomes. J. Pept. Sci. 11(11), 707-712 (2005).
83. Mayr A. [Historical review of smallpox, the eradication of smallpox and the attenuated smallpox MVA vaccine]. Berl. Munch. Tierarztl. Wochenschr. 112(9), 322-328 (1999).
84. Paoletti E. Applications of pox virus vectors to vaccination: an update. Proc. Natl Acad. Sci. USA 93(21), 11349-11353 (1996).
85. Gilbert SC, Schneider J, Hannan CM et al. Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine 20(7-8), 1039-1045 (2002).
86. Tatsis N, Ertl HC. Adenoviruses as vaccine vectors. Mol. Ther. 10(4), 616-629 (2004).
87. Schneider J, Langermans JA, Gilbert SC et al. A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees. Vaccine 19(32), 4595-4602 (2001).
88. McShane H, Pathan AA, Sander CR et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat. Med. 10(11), 1240-1244 (2004).
89. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408(6812), 605-609 (2000).
90. Commission for Africa www.commissionforafrica.org
91. Rollback Malaria Partnership www.rollbackmalaria.org
92. Stop TB Partnership www.stoptb.org
93. Bill & Melinda Gates Foundation www.gatesfoundation.org
94. The Global Fund to fight AIDS, tuberculosis and malaria www.theglobalfund.org